JP2018515106A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515106A5 JP2018515106A5 JP2017559428A JP2017559428A JP2018515106A5 JP 2018515106 A5 JP2018515106 A5 JP 2018515106A5 JP 2017559428 A JP2017559428 A JP 2017559428A JP 2017559428 A JP2017559428 A JP 2017559428A JP 2018515106 A5 JP2018515106 A5 JP 2018515106A5
- Authority
- JP
- Japan
- Prior art keywords
- gene encoding
- promoter
- genetically engineered
- gene
- pal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 claims 52
- 108090000623 proteins and genes Proteins 0.000 claims 51
- 108010078791 Carrier Proteins Proteins 0.000 claims 19
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 19
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 claims 19
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 19
- 201000011252 Phenylketonuria Diseases 0.000 claims 10
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000007613 environmental effect Effects 0.000 claims 6
- 230000006698 induction Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 230000007812 deficiency Effects 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 3
- 239000013612 plasmid Substances 0.000 claims 3
- BOEUHAUGJSOEDZ-UHFFFAOYSA-N 2-amino-5,6,7,8-tetrahydro-1h-pteridin-4-one Chemical compound N1CCNC2=C1C(=O)N=C(N)N2 BOEUHAUGJSOEDZ-UHFFFAOYSA-N 0.000 claims 2
- 208000018542 Dihydropteridine reductase deficiency Diseases 0.000 claims 2
- 208000014252 Mild phenylketonuria Diseases 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000026770 mild hyperphenylalaninemia Diseases 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 claims 1
- 241000606125 Bacteroides Species 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 241000186000 Bifidobacterium Species 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 241000194036 Lactococcus Species 0.000 claims 1
- 241000078013 Trichormus variabilis Species 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 238000004020 luminiscence type Methods 0.000 claims 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 claims 1
- 101150077062 pal gene Proteins 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021027597A JP7245271B2 (ja) | 2015-05-13 | 2021-02-24 | 高フェニルアラニン血症を低減させるように操作された細菌 |
| JP2023037515A JP7592777B2 (ja) | 2015-05-13 | 2023-03-10 | 高フェニルアラニン血症を低減させるように操作された細菌 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562161137P | 2015-05-13 | 2015-05-13 | |
| US62/161,137 | 2015-05-13 | ||
| US201562256052P | 2015-11-16 | 2015-11-16 | |
| US62/256,052 | 2015-11-16 | ||
| PCT/US2016/032562 WO2016183531A1 (en) | 2015-05-13 | 2016-05-13 | Bacteria engineered to reduce hyperphenylalaninemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021027597A Division JP7245271B2 (ja) | 2015-05-13 | 2021-02-24 | 高フェニルアラニン血症を低減させるように操作された細菌 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515106A JP2018515106A (ja) | 2018-06-14 |
| JP2018515106A5 true JP2018515106A5 (enExample) | 2019-06-13 |
| JP6843768B2 JP6843768B2 (ja) | 2021-03-17 |
Family
ID=56117975
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017559428A Active JP6843768B2 (ja) | 2015-05-13 | 2016-05-13 | 高フェニルアラニン血症を低減させるように操作された細菌 |
| JP2021027597A Active JP7245271B2 (ja) | 2015-05-13 | 2021-02-24 | 高フェニルアラニン血症を低減させるように操作された細菌 |
| JP2023037515A Active JP7592777B2 (ja) | 2015-05-13 | 2023-03-10 | 高フェニルアラニン血症を低減させるように操作された細菌 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021027597A Active JP7245271B2 (ja) | 2015-05-13 | 2021-02-24 | 高フェニルアラニン血症を低減させるように操作された細菌 |
| JP2023037515A Active JP7592777B2 (ja) | 2015-05-13 | 2023-03-10 | 高フェニルアラニン血症を低減させるように操作された細菌 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US10610546B2 (enExample) |
| EP (2) | EP3882259A1 (enExample) |
| JP (3) | JP6843768B2 (enExample) |
| AU (3) | AU2016262569B9 (enExample) |
| BR (1) | BR112017024384A2 (enExample) |
| CA (1) | CA2985819A1 (enExample) |
| ES (1) | ES2881384T3 (enExample) |
| IL (2) | IL296538A (enExample) |
| PL (1) | PL3294760T3 (enExample) |
| SG (1) | SG10202003100XA (enExample) |
| WO (1) | WO2016183531A1 (enExample) |
| ZA (1) | ZA201707678B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015153102A1 (en) | 2014-04-01 | 2015-10-08 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
| US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US10610546B2 (en) * | 2015-05-13 | 2020-04-07 | Synlogic Operating Company Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| US20160206666A1 (en) | 2014-12-22 | 2016-07-21 | Synlogic, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier |
| DE112016002056T5 (de) | 2015-05-06 | 2018-02-08 | Snipr Technologies Limited | Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen |
| EP3294757B1 (en) * | 2015-05-13 | 2023-12-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| US11883439B2 (en) | 2015-05-13 | 2024-01-30 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| US11685925B2 (en) | 2015-10-30 | 2023-06-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
| EP3377518B1 (en) * | 2015-11-16 | 2022-04-13 | Synlogic Operating Company, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
| WO2018112194A1 (en) | 2016-12-15 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating growth of a genetically modified gut bacterial cell |
| US11384358B2 (en) | 2017-03-29 | 2022-07-12 | President And Fellows Of Harvard College | Method of regulating gene expression in a cell |
| WO2018191715A2 (en) * | 2017-04-14 | 2018-10-18 | Synthetic Genomics, Inc. | Polypeptides with type v crispr activity and uses thereof |
| AU2018290278B2 (en) * | 2017-06-21 | 2022-12-15 | Synlogic Operating Company, Inc. | Bacteria for the treatment of disorders |
| JP7003232B2 (ja) | 2017-09-08 | 2022-02-04 | ニュー ポータル リミテッド | グルコース依存性の生存率を介して、細菌が固形腫瘍を特異的に標的とすることを可能にする核酸システム |
| US10849938B2 (en) | 2017-09-13 | 2020-12-01 | ZBiotics Company | Gene expression system for probiotic microorganisms |
| CN107904222B (zh) * | 2017-11-30 | 2019-10-08 | 江南大学 | 一种热稳定性提高的l-氨基酸脱氨酶突变体及其构建方法 |
| EP3720458A4 (en) * | 2017-12-05 | 2021-12-08 | BioPlx, Inc. | METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2019396366A1 (en) | 2018-12-10 | 2021-07-15 | Tenza, Inc. | Methods and compositions for treating hyperoxaluria |
| US20220047654A1 (en) * | 2018-12-20 | 2022-02-17 | University Of South Carolina | Pharmabiotic treatments for metabolic disorders |
| KR20220003030A (ko) * | 2019-04-29 | 2022-01-07 | 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 | 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수 |
| AU2020288624B2 (en) | 2019-06-04 | 2025-09-25 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| CN114450403A (zh) * | 2019-06-21 | 2022-05-06 | 银杏生物制品公司 | 用于在枫糖尿症(msud)的治疗中使用的酶的生物合成 |
| CN110257291B (zh) * | 2019-06-25 | 2021-07-23 | 北京大学 | 一株耐受镍离子毒性的无色杆菌及其应用 |
| CN114761028A (zh) | 2019-09-27 | 2022-07-15 | 英特瑞克斯顿阿克图比奥帝克斯有限公司 | 乳糜泻的治疗 |
| EP4058578A2 (en) | 2019-11-12 | 2022-09-21 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| KR20220130719A (ko) | 2020-01-17 | 2022-09-27 | 위니베르시트카솔리끄드루뱅 | 엔벨로프 완전성이 변화된 유전자 변형 세균 및 이의 용도 |
| WO2021173808A1 (en) * | 2020-02-25 | 2021-09-02 | Synlogic Operating Company, Inc. | Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof |
| BR112022018571A2 (pt) | 2020-03-20 | 2022-11-01 | Synlogic Operating Co Inc | Microrganismos manipulados para reduzir a hiperfenilalaninemia |
| WO2021207647A1 (en) * | 2020-04-09 | 2021-10-14 | Computational International LLC | Small molecule drugs as targeted therapeutics |
| CA3188581A1 (en) * | 2020-07-02 | 2022-01-06 | The Regents Of The University Of California | Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways |
| WO2022006748A1 (en) | 2020-07-07 | 2022-01-13 | New Portal Limited | Genetically engineered live bacteria and methods of constructing the same |
| EP4196139A2 (en) | 2020-08-12 | 2023-06-21 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| US20230332164A1 (en) * | 2020-09-30 | 2023-10-19 | Synlogic Operating Company, Inc. | Bacteria engineered to secrete active proteins |
| EP4243834A4 (en) * | 2020-11-10 | 2025-05-14 | Palena Therapeutics, Inc. | Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use |
| AU2021393455A1 (en) | 2020-12-02 | 2023-06-29 | Synlogic Operating Company, Inc. | Engineered microorganisms |
| CN112501098B (zh) * | 2020-12-11 | 2023-01-03 | 上海陶宇晟生物技术有限责任公司 | 具有降解苯丙氨酸能力的工程益生菌 |
| CN116847860A (zh) | 2020-12-31 | 2023-10-03 | 同生运营公司 | 经工程化以减轻高苯丙氨酸血症的微生物 |
| CN112662606A (zh) * | 2021-01-06 | 2021-04-16 | 中国科学院分子植物科学卓越创新中心 | 用于治疗苯丙酮尿症的工程益生菌 |
| CN112662607A (zh) * | 2021-01-07 | 2021-04-16 | 上海陶宇晟生物技术有限责任公司 | 具备表面展示苯丙氨酸解氨酶的工程益生菌 |
| US20240285699A1 (en) * | 2021-06-24 | 2024-08-29 | Lonza Greenwood Llc | Method to Control Administration of Active Substance to the Digestive Tract |
| JP2024542173A (ja) | 2021-11-09 | 2024-11-13 | アクティム・セラピューティクス・インコーポレイテッド | マクロファージを処置に適している表現型に変換するための免疫刺激細菌および処置のための対象の同定のためのコンパニオン診断法 |
| CN116836899A (zh) * | 2022-03-02 | 2023-10-03 | 和度生物技术(上海)有限公司 | 一种用于治疗高苯丙氨酸血症的工程微生物及其用途 |
| CN114717172B (zh) * | 2022-03-21 | 2022-09-23 | 江南大学 | 合成l-缬氨酸的大肠杆菌及其构建方法与应用 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| CN116463362B (zh) * | 2023-06-15 | 2023-09-19 | 中国中医科学院中药研究所 | 一种细胞分裂抑制剂的制备方法 |
| WO2025170927A1 (en) * | 2024-02-06 | 2025-08-14 | The Cleveland Clinic Foundation | Kynurenine responsive bacteria and cancer therapies |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| CN1154845A (zh) | 1996-09-09 | 1997-07-23 | 首都医学院附属北京红十字朝阳医院 | 能表达活性苯丙氨酸脱氨酶的基因工程菌口服制剂 |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| EP1135461A4 (en) | 1998-12-02 | 2003-03-26 | Univ Boston | GEN NETWORKS FOR CONTROLLING GENE EXPRESSION |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| JP4682454B2 (ja) | 2000-06-28 | 2011-05-11 | 味の素株式会社 | 新規変異型ｎ−アセチルグルタミン酸合成酵素及びｌ−アルギニンの製造法 |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| JP4347575B2 (ja) | 2001-05-03 | 2009-10-21 | アクトジェニックス・エヌブイ | 自己自制ラクトコッカス（Ｌｏｃｔｏｃｏｃｃｕｓ）株 |
| US7314974B2 (en) | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| JP4452914B2 (ja) | 2003-09-08 | 2010-04-21 | 味の素株式会社 | 新規トランスポータタンパク質 |
| CA2559760A1 (en) | 2004-07-02 | 2006-07-06 | Metanomics Gmbh | Process for the production of fine chemicals |
| US7553653B2 (en) | 2004-09-17 | 2009-06-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| CN101068919B (zh) | 2004-11-30 | 2011-08-10 | Aeras全球Tb疫苗基金会 | 适用于产生和制备重组双链rna核壳的细菌包装菌株及其用途 |
| GB0501540D0 (en) | 2005-01-25 | 2005-03-02 | Univ Leeds | Controlled production and delivery of biologically active agents by gut bacteria |
| EP1869174B1 (en) | 2005-03-10 | 2015-02-18 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| CA2653967A1 (en) | 2006-06-02 | 2008-10-02 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| US9084434B2 (en) | 2006-09-27 | 2015-07-21 | Little Calumet Holdings Llc | Probiotic oral dosage forms |
| US20100297249A1 (en) | 2007-07-05 | 2010-11-25 | North-West University | Enhancement of the efficacy of therapeutic proteins |
| CN101586111B (zh) * | 2008-05-22 | 2012-03-07 | 北京三元基因工程有限公司 | 一种活性乳酸乳球菌制品的制备方法 |
| EP2344626B1 (en) | 2008-09-29 | 2017-03-29 | Intrexon Actobiotics NV | Reduced colonization of microbes at the mucosa |
| CA3121387A1 (en) | 2009-08-04 | 2011-02-10 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same forincreasing abiotic stress tolerance, yield, growth rate, vigor, biomass oil content, and/or nitrogen use efficiency of plants |
| WO2011080505A2 (en) | 2009-12-28 | 2011-07-07 | Bigdna Ltd | Method of growing phage for commercial use |
| WO2011106874A1 (en) | 2010-03-02 | 2011-09-09 | Functional Technologies Corp. | Functional enhancement of microorganisms to minimize production of acrylamide |
| US8129170B1 (en) | 2010-12-06 | 2012-03-06 | E.I. Du Pont De Nemours And Company | Recombinant bacteria having the ability to metabolize sucrose |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| US9017961B2 (en) | 2012-03-05 | 2015-04-28 | E.I. Du Pont De Nemours And Company | Recombinant bacteria comprising novel sucrose transporters |
| FR2990699B1 (fr) | 2012-05-21 | 2016-02-05 | Agronomique Inst Nat Rech | Cassettes d'expression procaryotes regulees par le stress |
| CN104487581B (zh) * | 2012-06-22 | 2021-05-28 | 菲特吉恩公司 | 用于苯乙烯合成的酶和方法 |
| CA2880620A1 (en) * | 2012-07-27 | 2014-01-30 | University Of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (pku) disease |
| US20150246085A1 (en) * | 2012-11-01 | 2015-09-03 | The Sydney Children's Hospital Network (Randwick & Westmead) | Genetically-Modified Probiotic for Treatment of Phenylketonuria |
| CA2894710A1 (en) | 2012-12-13 | 2014-06-19 | Massachusetts Institute Of Technology | Recombinase-based logic and memory systems |
| WO2014138324A1 (en) | 2013-03-07 | 2014-09-12 | The General Hospital Corporation | Compositions and methods for bacterial delivery of polypeptides |
| SG11201508598YA (en) | 2013-04-18 | 2015-11-27 | Codexis Inc | Engineered phenylalanine ammonia lyase polypeptides |
| BR112017011923A2 (pt) * | 2014-12-05 | 2018-02-27 | Synlogic Inc | bactéria modificada para tratar doenças associadas com hiperamonemia |
| US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US10610546B2 (en) | 2015-05-13 | 2020-04-07 | Synlogic Operating Company Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| EP3294757B1 (en) | 2015-05-13 | 2023-12-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| CA2987508A1 (en) | 2015-05-28 | 2016-12-01 | Evolva Sa | Biosynthesis of phenylpropanoids and phenylpropanoid derivatives |
| EP3307870B1 (en) * | 2015-06-10 | 2023-08-02 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid |
| WO2016210373A2 (en) * | 2015-06-24 | 2016-12-29 | Synlogic, Inc. | Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof |
| US20170216370A1 (en) | 2015-07-31 | 2017-08-03 | Synlogic, Inc. | Bacteria engineered to treat disorders involving propionate catabolism |
| EP3377518B1 (en) | 2015-11-16 | 2022-04-13 | Synlogic Operating Company, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| US10982223B2 (en) | 2016-06-13 | 2021-04-20 | Benson Hill, Inc. | Increasing plant growth and yield by using a phenylalanine ammonia lyase sequence |
| AU2018290278B2 (en) | 2017-06-21 | 2022-12-15 | Synlogic Operating Company, Inc. | Bacteria for the treatment of disorders |
| CA3105916A1 (en) | 2018-07-12 | 2020-01-16 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| BR112022018571A2 (pt) | 2020-03-20 | 2022-11-01 | Synlogic Operating Co Inc | Microrganismos manipulados para reduzir a hiperfenilalaninemia |
| CN116847860A (zh) | 2020-12-31 | 2023-10-03 | 同生运营公司 | 经工程化以减轻高苯丙氨酸血症的微生物 |
| WO2023044479A1 (en) | 2021-09-17 | 2023-03-23 | Synlogic Operating Company, Inc. | Methods for reducing hyperphenylalaninemia |
-
2016
- 2016-05-13 US US15/154,934 patent/US10610546B2/en active Active
- 2016-05-13 WO PCT/US2016/032562 patent/WO2016183531A1/en not_active Ceased
- 2016-05-13 PL PL16728448T patent/PL3294760T3/pl unknown
- 2016-05-13 ES ES16728448T patent/ES2881384T3/es active Active
- 2016-05-13 EP EP21156322.6A patent/EP3882259A1/en active Pending
- 2016-05-13 AU AU2016262569A patent/AU2016262569B9/en active Active
- 2016-05-13 JP JP2017559428A patent/JP6843768B2/ja active Active
- 2016-05-13 SG SG10202003100XA patent/SG10202003100XA/en unknown
- 2016-05-13 CA CA2985819A patent/CA2985819A1/en active Pending
- 2016-05-13 EP EP16728448.8A patent/EP3294760B1/en active Active
- 2016-05-13 US US15/319,564 patent/US9889164B2/en active Active
- 2016-05-13 BR BR112017024384A patent/BR112017024384A2/pt not_active Application Discontinuation
- 2016-05-13 US US15/301,324 patent/US10195234B2/en active Active
- 2016-05-13 IL IL296538A patent/IL296538A/en unknown
- 2016-09-08 US US15/260,211 patent/US9943555B2/en active Active
-
2017
- 2017-11-12 IL IL255616A patent/IL255616B2/en unknown
- 2017-11-13 ZA ZA2017/07678A patent/ZA201707678B/en unknown
- 2017-12-22 US US15/852,762 patent/US10933102B2/en active Active
-
2020
- 2020-02-12 US US16/788,458 patent/US12409195B2/en active Active
-
2021
- 2021-02-24 JP JP2021027597A patent/JP7245271B2/ja active Active
- 2021-08-06 AU AU2021212141A patent/AU2021212141B2/en active Active
-
2023
- 2023-03-10 JP JP2023037515A patent/JP7592777B2/ja active Active
-
2024
- 2024-12-18 AU AU2024278562A patent/AU2024278562A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515106A5 (enExample) | ||
| US11896627B2 (en) | Bacteria engineered to treat metabolic diseases | |
| US20220233609A1 (en) | Bacteria engineered to treat disorders in which oxalate is detrimental | |
| EP3307870B1 (en) | Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid | |
| JP6768689B2 (ja) | 高アンモニア血症に関連する病気を処置するために操作された細菌 | |
| US20210095297A1 (en) | Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier | |
| CN112041427B (zh) | 合生元组合物 | |
| ES2881384T3 (es) | Bacterias manipuladas para reducir la hiperfenilalaninemia | |
| JP2018504919A5 (enExample) | ||
| JP6817966B2 (ja) | 高アンモニア血症に関連する疾患を治療するために操作された細菌 | |
| Watson et al. | Enhancing bile tolerance improves survival and persistence of Bifidobacterium and Lactococcus in the murine gastrointestinal tract | |
| AU2016226234A1 (en) | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | |
| EP3294757A1 (en) | Bacteria engineered to treat a disease or disorder | |
| JP2018523978A5 (enExample) | ||
| WO2022121968A1 (zh) | 具有降解苯丙氨酸能力的工程益生菌 | |
| US20230105474A1 (en) | Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof | |
| Alexander et al. | Exploiting prophage-mediated lysis for biotherapeutic release by Lactobacillus reuteri | |
| US20240382536A1 (en) | Bacteria engineered to treat a disease or disorder | |
| US20230090705A1 (en) | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | |
| US11696931B2 (en) | Bacteria for targeting tumors and treating cancer | |
| JP2018521674A5 (enExample) | ||
| WO2022148362A1 (zh) | 具备表面展示苯丙氨酸解氨酶的工程益生菌 | |
| WO2016210378A2 (en) | Multi-layered control of gene expression in genetically engineered bacteria | |
| CA3140174A1 (en) | Synergistic combinations of arginine-producing bacteria and/or ammonia-consuming bacteria and checkpoint inhibitors and methods of use thereof | |
| US20240110191A1 (en) | Engineered microorganisms |